Filing Analysis
Other SEC Filing
Filed Apr 13, 2026
MEDIUM
ALX Oncology Holdings Inc. has appointed Jeff Knight as Chief Development and Operating Officer, effective April 13, 2026. Mr. Knight brings over 25 years of experience from companies including Crinetics Pharmaceuticals, Amgen, and Genentech, and will receive a base salary of $565,000 plus 800,000 stock options.
Key Facts
- Jeff Knight appointed as Chief Development and Operating Officer effective April 13, 2026.
- Annual base salary set at $565,000 with a 40% target annual cash bonus.
- Granted a stock option to purchase 800,000 shares under the 2025 Inducement Equity Incentive Plan.
- Mr. Knight previously served as CDOO at Crinetics Pharmaceuticals and held leadership roles at Amgen and Genentech.
Regulation FD Disclosure
Filed Feb 27, 2026
LOW
ALX Oncology Holdings Inc. announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The results were disclosed via a press release furnished with the SEC filing.
Key Facts
- Financial results for Q4 and full year 2025 announced on February 27, 2026
- Information furnished under Item 2.02 Results of Operations and Financial Condition
- Press release included as Exhibit 99.1
- Filing signed by CFO Harish Shantharam
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.